Home > Insider Trading > Filing (0001209191-16-142026)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
906709	Nektar Therapeutics	NKTR	Pharmaceutical Preparations (2834)	943134940

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1229877	A Christopher Kuebler	C/O Nektar Therapeutics 455 Mission Bay Boulevard Sout San Francisco CA 94158		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-09-15	15,000	$0.00	35,000	No	4	M	Direct
Common Stock	Disposition	2016-09-16	7,500	$19.13	27,500	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2016-09-15	15,000	$0.00	15,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date.
The total holdings include 15,000 shares of restricted stock units ("RSUs") that were previously reported in Table II for the reporting person and which are being reclassified to Table I. These RSUs were granted on September 15, 2015, are convertible on a one-for-one basis into shares of Common Stock of the Company and vested on September 15, 2016.
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This transaction was executed in multiple trades at prices ranging from $18.94 to $19.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.